Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20292599 | 0.86 | MGLL (0.33) | MEN1LMNACYP3A4CYP2C9NFKB1 | |
| SCHEMBL2193456 | 0.82 | MEN1 (0.35) | MEN1LMNACYP3A4CYP2C9NFKB1 | |
| SCHEMBL2147484 | 0.78 | KMT2A (0.31) | MEN1LMNACYP3A4CYP2C9NFKB1 | |
| SCHEMBL915632 | 0.78 | KMT2A (0.33) | MEN1LMNACYP3A4CYP2C9NFKB1 | |
| SCHEMBL2147485 | 0.78 | CYP3A4 (0.35) | MEN1LMNACYP3A4CYP2C9NFKB1 | |
| SCHEMBL4700256 | 0.76 | LMNA (0.30) | MEN1LMNACYP3A4CYP2C9NFKB1 | |
| SCHEMBL4821013 | 0.76 | ALOX12 (0.33) | MEN1LMNACYP3A4CYP2C9NFKB1 | |
| SCHEMBL258692 | 0.75 | MGLL (0.36) | MEN1LMNACYP3A4CYP2C9NFKB1 | |
| SCHEMBL1764576 | 0.74 | KMT2A (0.49) | MEN1LMNACYP3A4CYP2C9NFKB1 | |
| SCHEMBL12107373 | 0.73 | MGLL (0.34) | MEN1LMNACYP3A4CYP2C9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250143-B1 | METHOD FOR THE ENZYMATIC KINETIC RESOLUTION OF ACYLOXYALKYL THIOCARBONATES USED FOR THE SYNTHESIS OF ACYLOXYALKYL CARBAMATES | XENOPORT INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8062870-B2 | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs | XENOPORT, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2250143-A2 | METHOD FOR THE ENZYMATIC KINETIC RESOLUTION OF ACYLOXYALKYL THIOCARBONATES USED FOR THE SYNTHESIS OF ACYLOXYALKYL CARBAMATES | XenoPort, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090192325-A1 | ENANTIOMERICALLY RESOLVING ACYLOXYALKYL THIOCARBONATES USED IN SYNTHESIZING ACYLOXYALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2009094569-A2 | METHOD FOR THE ENZYMATIC KINETIC RESOLUTION OF ACYLOXYALKYL THIOCARBONATES USED FOR THE SYNTHESIS OF ACYLOXYALKYL CARBAMATES | XENOPORT, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192325-A1 | ENANTIOMERICALLY RESOLVING ACYLOXYALKYL THIOCARBONATES USED IN SYNTHESIZING ACYLOXYALKYL CARBAMATE PRODRUGS | AADAC, NAAA, APEH | MEN1 3876/4885LMNA 4118/4885CYP3A4 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.